For instance, the GPR3 agonist would be predicted to decrease anxiety- and depression-like behaviors based on this prior study, which could make the agonist an even more attractive target for nicotine therapeutics, as nicotine use is often associated with anxiety and depression in humans [30]. Here, GPR3 is linked to depressive disorder.